Literature DB >> 9635605

Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation.

J I Herrero1, J Quiroga, B Sangro, I Sola, J I Riezu-Boj, F Pardo, J Prieto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9635605     DOI： 10.1023/a:1018887203545

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  11 in total

1.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  R P Perrillo; E R Schiff; G L Davis; H C Bodenheimer; K Lindsay; J Payne; J L Dienstag; C O'Brien; C Tamburro; I M Jacobson; R Sampliner; D Feit; J Lefkowitch; M Kuhns; C Meschievitz; B Sanghvi; J Albrecht; A Gibas
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

2.  Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.

Authors:  L Grellier; D Mutimer; M Ahmed; D Brown; A K Burroughs; K Rolles; P McMaster; P Beranek; F Kennedy; H Kibbler; P McPhillips; E Elias; G Dusheiko
Journal:  Lancet       Date:  1996-11-02       Impact factor: 79.321

3.  Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients.

Authors:  D Samuel; A Bismuth; D Mathieu; J L Arulnaden; M Reynes; J P Benhamou; C Brechot; H Bismuth
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

4.  Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.

Authors:  Y Benhamou; E Dohin; F Lunel-Fabiani; T Poynard; J M Huraux; C Katlama; P Opolon; M Gentilini
Journal:  Lancet       Date:  1995-02-11       Impact factor: 79.321

5.  A preliminary trial of lamivudine for chronic hepatitis B infection.

Authors:  J L Dienstag; R P Perrillo; E R Schiff; M Bartholomew; C Vicary; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

6.  High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis.

Authors:  J Y Lau; V G Bain; S E Davies; J G O'Grady; A Alberti; G J Alexander; R Williams
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

7.  Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients.

Authors:  R G Gish; J Y Lau; L Brooks; J W Fang; S L Steady; J C Imperial; R Garcia-Kennedy; C O Esquivel; E B Keeffe
Journal:  Hepatology       Date:  1996-01       Impact factor: 17.425

8.  Liver transplantation in European patients with the hepatitis B surface antigen.

Authors:  D Samuel; R Muller; G Alexander; L Fassati; B Ducot; J P Benhamou; H Bismuth
Journal:  N Engl J Med       Date:  1993-12-16       Impact factor: 91.245

9.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

Authors:  R McKenzie; M W Fried; R Sallie; H Conjeevaram; A M Di Bisceglie; Y Park; B Savarese; D Kleiner; M Tsokos; C Luciano
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

10.  Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection.

Authors:  A S Lok; L A Wilson; H C Thomas
Journal:  J Antimicrob Chemother       Date:  1984-07       Impact factor: 5.790
View more
  1 in total

Review 1.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.